ArticleTranslational cancer research2026
CNN3 promotes angiogenesis in osteosarcoma, associated with upregulating VEGF-A and enhancing endothelial cell activity.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiogenesis plays a pivotal role in driving tumour progression, including tumour growth, local invasion, and distant metastasis. Calponin 3 (CNN3) belongs to the actin-binding protein family and has been shown to be aberrantly expressed in osteosarcoma specimens, but its exact role in the regulation of angiogenesis remains unknown. This study aimed to investigate the function and underlying mechanism of CNN3 in osteosarcoma angiogenesis. Methods: CNN3 and CD31 expression in osteosarcoma specimens was detected by immunohistochemistry. CNN3 in MG-63 and Saos-2 cells was silenced or overexpressed by transfection with small interfering RNA or overexpression plasmids, respectively. Vascular endothelial growth factor-A (VEGF-A) levels were determined by enzyme-linked immunosorbent assay. Human umbilical vein endothelial cells (HUVECs) were co-cultured with CNN3-silenced or -overexpressing osteosarcoma cells using a Transwell chamber. The function of HUVECs were assessed using cell counting, scratch wound healing, Transwell Matrigel invasion, and Matrigel vascular mimicry assays. The protein levels of endothelial-to-mesenchymal transition (EndMT) markers and phosphorylated Akt in HUVECs was determined using western blotting. Results: Immunohistochemical analysis demonstrated a significant positive correlation between CNN3 expression and CD31 (microvascular density marker) levels in osteosarcoma tissues (r=0.7264, P=0.0003). HUVECs co-cultured with CNN3-overexpressing cells exhibited enhanced proliferative, migratory, invasive, and tube-forming capacities along with promoted EndMT, whereas CNN3 silencing suppressed these effects. CNN3 silencing reduced, while its overexpression elevated, VEGF-A secretion in both MG-63 and Saos-2 cells. Furthermore, silencing CNN3 in MG-63 and Saos-2 cells decreased Akt phosphorylation in co-cultured HUVECs, whereas CNN3 overexpression concomitantly increased it. Conclusions: CNN3 promotes osteosarcoma angiogenesis, possibly through upregulating VEGF-A secretion and enhancing endothelial cell functions, suggesting its potential as the therapeutic target for anti-angiogenic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.